Contact
searchSearch
HMP Global
Conference Coverage
Open-label Study Finds DaxibotulinumtoxinA for Injection Safe for Glabellar Lines
06/26/2020
Researchers found that daxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin in development, is safe with high response rates in the treatment of glabellar lines. The study confirmed the results...
Researchers found that daxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin in development, is safe with high response rates in the treatment of glabellar lines. The study confirmed the results...
...
06/26/2020
The Dermatologist
Videos
Dr Katz on Neuromodulators and Cosmetic Dermatology
06/23/2020
Bruce M. Katz, MD, discusses the results of two phase 3 clinical trials on daxibotulinumtoxinA for injection, the development of a onabotulinumtoxinA biosimilar, and the current state and future of cosmetic dermatology practice.
Bruce M. Katz, MD, discusses the results of two phase 3 clinical trials on daxibotulinumtoxinA for injection, the development of a onabotulinumtoxinA biosimilar, and the current state and future of cosmetic dermatology practice.
Bruce M. Katz, MD, discusses the...
06/23/2020
The Dermatologist
Conference Coverage
ABCD Criteria Still Effective, Study Shows
06/15/2020
While the “ABCD” acronym (Asymmetry, Border, Color, Diameter) was developed more than 35 years ago, modern clinicians may wonder if its use is still warranted with the number of new tools available. A poster...
While the “ABCD” acronym (Asymmetry, Border, Color, Diameter) was developed more than 35 years ago, modern clinicians may wonder if its use is still warranted with the number of new tools available. A poster...
While...
06/15/2020
The Dermatologist
Conference Coverage
Survey Finds Patients Most Satisfied With IL-17 Inhibitors, 4-Week Dosing
06/15/2020
A recent study found that patients had the highest overall treatment satisfaction with anti-IL-17 class therapies. The poster, presented at the American Academy of Dermatology Virtual Meeting Experience 2020, also...
A recent study found that patients had the highest overall treatment satisfaction with anti-IL-17 class therapies. The poster, presented at the American Academy of Dermatology Virtual Meeting Experience 2020, also...
A...
06/15/2020
The Dermatologist
Conference Coverage
Abrocitinib Rapidly Improves Pruritus in Patients with Atopic Dermatitis
06/15/2020
Findings from a recent poster abstract presented at the American Academy of Dermatology Virtual Meeting Experience 2020 showed promising results for abrocitinib, an oral Janus kinase inhibitor.
Findings from a recent poster abstract presented at the American Academy of Dermatology Virtual Meeting Experience 2020 showed promising results for abrocitinib, an oral Janus kinase inhibitor.
Findings from a recent poster...
06/15/2020
The Dermatologist
Conference Coverage
Cannabis Used to Treat Inflammatory and Pruritic Conditions
06/15/2020
A research group out of Washington state presented their findings on cannabis use among dermatology patients at the AAD VMX 2020.
A research group out of Washington state presented their findings on cannabis use among dermatology patients at the AAD VMX 2020.
A research group out of...
06/15/2020
The Dermatologist
Conference Coverage
Patients With Alopecia Using More Supplements Per Day, Study Finds
06/15/2020
Findings from a recent poster abstract highlighted the the amount of supplements patients with alopecia would take in a day compared with the general population.
Findings from a recent poster abstract highlighted the the amount of supplements patients with alopecia would take in a day compared with the general population.
Findings from a recent poster...
06/15/2020
The Dermatologist
Conference Coverage
Baricitinib Improves Itch, QoL for Patients with Atopic Dermatitis
06/14/2020
As an oral selective inhibitor of Januse kinase (JAK) 1 and JAK 2, which may play a role in the inflammatory response of atopic dermatitis (AD), baricitinib is under investigation for the treatment of moderate to...
As an oral selective inhibitor of Januse kinase (JAK) 1 and JAK 2, which may play a role in the inflammatory response of atopic dermatitis (AD), baricitinib is under investigation for the treatment of moderate to...
As an...
06/14/2020
The Dermatologist
Conference Coverage
Type A Botulinum Toxin Study Demonstrates Safety in Clinical Research for Naïve and Treatment-experienced Patients
06/14/2020
Glabellar lines are one of the most commonly requested sites for neuromodulator injection, and clinical trials for a new type A botulinum toxin (BoNTA), daxibotulinumtoxinA (DAXI), demonstrated similar safety and...
Glabellar lines are one of the most commonly requested sites for neuromodulator injection, and clinical trials for a new type A botulinum toxin (BoNTA), daxibotulinumtoxinA (DAXI), demonstrated similar safety and...
...
06/14/2020
The Dermatologist
Conference Coverage
Once-Daily Tazarotene Formula 0.045% Effective for Moderate to Severe Acne
06/14/2020
Researchers have found that once-daily tazarotene 0.045% is efficacious with a favorable safety and tolerability profile for the treatment of moderate to severe acne. The results of a pivotal, 12-week, phase 3 study...
Researchers have found that once-daily tazarotene 0.045% is efficacious with a favorable safety and tolerability profile for the treatment of moderate to severe acne. The results of a pivotal, 12-week, phase 3 study...
...
06/14/2020
The Dermatologist
Conference Coverage
Trial Results Show Efficacy, Safety, Durability of Bimekizumab
06/13/2020
Data on the efficacy and safety of bimekizumab from 2 phase 3 clinical trials presented at the American Academy of Dermatology Virtual Meeting Experience 2020 showed promising results for the treatment of moderate to severe plaque psoriasis.
Data on the efficacy and safety of bimekizumab from 2 phase 3 clinical trials presented at the American Academy of Dermatology Virtual Meeting Experience 2020 showed promising results for the treatment of moderate to severe plaque psoriasis.
Data on the efficacy and safety...
06/13/2020
The Dermatologist
A Virtual Experience for the Modern Dermatologist
06/11/2020
In early March, the 2020 Annual American Academy of Dermatology (AAD) Meeting was canceled amid concerns over the spread of coronavirus disease (COVID-19). To meet the educational needs and plenary requirements...
In early March, the 2020 Annual American Academy of Dermatology (AAD) Meeting was canceled amid concerns over the spread of coronavirus disease (COVID-19). To meet the educational needs and plenary requirements...
In...
06/11/2020
The Dermatologist

Popular Articles

NEA Approved Features
The Impact of Atopic Dermatitis Symptoms on Mental Health
05/03/2024
Jessica Garlewicz
When patients are aware of the connection between their mental health and their eczema symptoms, they may be more likely to seek support.
When patients are aware of the connection between their mental health and their eczema symptoms, they may be more likely to seek support.
When patients are aware of the...
05/03/2024
The Dermatologist
News
Assessing Complications in Lip Augmentation With Dermal Fillers
06/06/2024
Riya Gandhi, MA; Jessica Garlewicz
Lip augmentation through dermal filler injections has become increasingly popular as a noninvasive cosmetic procedure.
Lip augmentation through dermal filler injections has become increasingly popular as a noninvasive cosmetic procedure.
Lip augmentation through dermal...
06/06/2024
The Dermatologist
psoriatic arthritis
News
Readmissions After Hospitalization for Psoriatic Arthritis
06/20/2024
Jessica Garlewicz
Researchers aimed to assess the rates, characteristics, and predictors of 30-day readmissions among adults hospitalized for psoriatic arthritis across the United States.
Researchers aimed to assess the rates, characteristics, and predictors of 30-day readmissions among adults hospitalized for psoriatic arthritis across the United States.
Researchers aimed to assess the...
06/20/2024
The Dermatologist
psoriasis
News
Long-Term Risankizumab Treatment for Moderate to Severe Plaque Psoriasis
08/22/2024
Jessica Garlewicz
Researchers assessed the long-term efficacy of risankizumab for moderate to severe plaque psoriasis.
Researchers assessed the long-term efficacy of risankizumab for moderate to severe plaque psoriasis.
Researchers assessed the...
08/22/2024
The Dermatologist
Case Report
Successful Treatment of Melasma in Fitzpatrick Skin Type IV
10/07/2024
Monica Khadka, BA, BS; Kerry C. Hennessy, MD; Lilia M. Correa-Selm, MD, FAAD
Nonablative Alexandrite laser therapy may be an effective method of treating melasma in patients with darker skin types.
Nonablative Alexandrite laser therapy may be an effective method of treating melasma in patients with darker skin types.
Nonablative Alexandrite laser...
10/07/2024
The Dermatologist
April/May 2026 cover

Current Issue

April 2026
Volume 34
Issue 3
Current Issue
Issue Archive

Latest Quizzes and Trivia

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use